Patents by Inventor Ana Castro Morera

Ana Castro Morera has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20170283378
    Abstract: The invention relates to substituted heterocyclic indole derivatives of Formula (I), which act as activators of the AMP-activated protein kinase (AMPK) and to the use of them for the treatment and prevention of diseases or disorders regulated by AMPK. As a result, these compounds can be used for the treatment of inflammatory, autoimmune, cardiovascular, neurological diseases and cancer.
    Type: Application
    Filed: September 18, 2015
    Publication date: October 5, 2017
    Applicants: Consejo Superior de Investigaciones Cientificas (CSIC), Centro de Investigacion Biomedica en Red (CIBER)
    Inventors: Ana Castro Morera, Pascual Sanz Bigorra, Marta Vela Ruiz, Maria Adelaida Garcia Gimeno
  • Patent number: 8686042
    Abstract: The invention relates to urea derivatives of formula (I) as inhibitors of glycogen synthase kinase 3?, GSK-3, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use for the treatment and or prophylaxis of a disease in which GSK-3 is involved, such as Alzheimer's disease or non-insulin dependent diabetes mellitus.
    Type: Grant
    Filed: July 28, 2006
    Date of Patent: April 1, 2014
    Assignee: Neuropharma, S.A.
    Inventors: Ana Martinez Gil, Miguel Medina Padilla, Mercedes Alonso Cascon, Ana Fuertes Huerta, Maria Luisa Navarro Rico, Maria Jose Perez Puerto, Ana Castro Morera, Ester Martin Aparicio
  • Publication number: 20140011835
    Abstract: The present invention relates to a new family of [1,10]-phenantroline derivatives of formula (I), which are useful for the treatment or prophylaxis of a neurodegenerative or hematological disease or condition, their use as a medicament, especially for treating a neurodegenerative or hematological disease or condition, and a pharmaceutical composition comprising the compounds.
    Type: Application
    Filed: September 15, 2013
    Publication date: January 9, 2014
    Applicant: Noscira, S.A.
    Inventors: Ana MARTINEZ GIL, Ana Castro Morera, Miguel Medina Padilla, Jorge Sanchez-Quesada, Mercedes Alonso Cascon, Laura Rubio Arrieta, Esther Garcia Palomero, Paola Usan Egea
  • Patent number: 8592446
    Abstract: The present invention relates to a new family of [1,10]-phenantroline derivatives of formula (I), which are useful for the treatment or profilaxis of a neurodegenerative or haematological disease or condition, their use as a medicament, especially for treating a treatment neurodegenerative or haematological disease or condition, and a pharmaceutical composition comprising the compounds.
    Type: Grant
    Filed: June 11, 2008
    Date of Patent: November 26, 2013
    Assignee: Noscira, S.A.
    Inventors: Ana Martinez Gil, Ana Castro Morera, Miguel Medina Padilla, Jorge Sanchez-Quesada, Mercedes Alonso Cascon, Laura Rubio Arrieta, Esther Garcia Palomero, Paola Usan Egea
  • Publication number: 20110306631
    Abstract: The present invention relates to a new family of triple substituted phenantroline derivatives of formula (I), which are useful for the treatment or profilaxis of a neurodegenerative or haematological disease or condition or cancer, their use as a medicament, especially for treating a neurodegenerative or haematological disease or condition or cancer, and a pharmaceutical composition comprising the compounds.
    Type: Application
    Filed: December 10, 2009
    Publication date: December 15, 2011
    Applicant: NOSCIRA, S.A.
    Inventors: Miguel Medina Padilla, Ana Castro Morera, Jorge Sánchez-Quesada, Esther García Palomero, Mercedes Alonso Cascón, Susana Herrero Santos, Marta Vela Ruíz, Paola Usán Egea, Ana Luisa Rodríguez Villanueva
  • Patent number: 8067441
    Abstract: The present invention relates to the use of Collismycin and derivatives thereof as inhibitors of oxidative stress in cells and their use for the preparation of medicaments for the treatment of oxidative stress-induced diseases or conditions, especially neurodegenerative diseases, such as Alzheimer's Disease and Parkinson's Disease.
    Type: Grant
    Filed: July 28, 2006
    Date of Patent: November 29, 2011
    Assignees: Neuropharma, S.A., Instituto Biomar, S.A.
    Inventors: Ana Martinez Gil, Paola Usan Egea, Miguel Medina Padilla, Esther Garcia Palomero, Julia Perez Baz, Rosa Isabel Fernandez Chimeno, Antonio Medarde Fernandez, Librada Maria Canedo Hernandez, Francisco Romero Millan, Ana Castro Morera, Mercedes Alonso Cascon, Jorge Sanchez Quesada
  • Publication number: 20110092591
    Abstract: The present invention is related to a family of phenyl-prenyl derivatives of formula (I), and to their use in the treatment of cognitive, neurodegenerative or neuronal diseases or disorders, such as Alzheimer's disease or Parkinson's Disease. The present invention also relates to pharmaceutical compositions comprising the same. Further, the present invention is directed to the compounds of formula (I) for medical use, particularly for the use for the treatment and/or prevention of a cognitive, neurodegenerative or neuronal disease or disorder, and to the use of the compounds in the manufacture of a medicament for the treatment and/or prevention of a cognitive, neurodegenerative or neuronal disease or disorder.
    Type: Application
    Filed: February 6, 2009
    Publication date: April 21, 2011
    Applicant: NOSCIRA S.A.
    Inventors: Javier Lopez Ogalla, Pilar Munoz Ruiz, Diana Alonso Gordillo, Miguel Medina Padilla, Esther Garcia Palomero, Ana Martinez Gil, Ana Castro Morera
  • Publication number: 20100267827
    Abstract: The present invention is related to a family of phenyl-prenyl-ether derivatives of formula (I), and to their use in the treatment of cognitive, neurodegenerative or neuronal diseases or disorders, such as Alzheimer's disease or 5 Parkinson's Disease. The present invention also relates to pharmaceutical compositions comprising the same. Further, the present invention is directed to the use of the compounds in the manufacture of a medicament for the treatment and/or prevention of a cognitive, neurodegenerative or neuronal disease or disorder.
    Type: Application
    Filed: August 1, 2007
    Publication date: October 21, 2010
    Applicant: NOSCIRA, S.A.
    Inventors: Ana Martinez Gil, Ana Castro Morera, Miguel Medina Padilla, Pilar Munoz Ruiz, Javier Lopez Ogalla, Laura Rubio Arrieta, Esther Garcia Palomero, Pablo Garcia Fernandez, Celia De Austria De Luque, Elena Delgado Hernandez, Paola Usan Egea, Rita Valenzuela Liminana, Jorge Sanchez-Quesada
  • Publication number: 20100240692
    Abstract: The present invention relates to a new family of [1,10]-phenantroline derivatives of formula (I), which are useful for the treatment or profilaxis of a neurodegenerative or haematological disease or condition, their use as a medicament, especially for treating a treatment neurodegenerative or haematological disease or condition, and a pharmaceutical composition comprising the compounds.
    Type: Application
    Filed: June 11, 2008
    Publication date: September 23, 2010
    Applicant: NOSCIRA, S.A.
    Inventors: Ana Martinez Gil, Ana Castro Morera, Miguel Medina Padilla, Jorge Sanchez-Quesada, Mercedes Alonso Cascon, Laura Rubio Arrieta, Esther Garcia Palomero, Paola Usan Egea
  • Patent number: 7781463
    Abstract: Compounds of general formula (I): where A, E, G, X, Y and the bond - - - take various meanings are of use in the preparation of a pharmaceutical formulation, for example in the treatment of a disease in which GSK-3 is involved, including Alzheimer's disease or the non-dependent insulin diabetes mellitus, or hyperproliferative disease such as cancer, displasias or metaplasias of tissue, psoriasis, arteriosclerosis or restenosis.
    Type: Grant
    Filed: April 20, 2007
    Date of Patent: August 24, 2010
    Assignees: Consejo Superior de Investigaciones Cientificas, Universidad Autonoma de Madrid (UAM)
    Inventors: Ana Martinez Gil, Ana Castro Morera, Maria Concepcion Martin Perez, Mercedes Alonso Cascon, Isabel Dorronsoro Diaz, Francisco Jose Moreno Munoz, Francisco Wandosell Jurado
  • Publication number: 20100048635
    Abstract: The present invention relates to the use of Collismycin and derivatives thereof as inhibitors of oxidative stress in cells and their use for the preparation of medicaments for the treatment and/or prevention of oxidative stress-induced diseases or conditions, especially neurodegenerative diseases, such as Alzheimer's Disease and Parkinson's Disease.
    Type: Application
    Filed: July 28, 2006
    Publication date: February 25, 2010
    Applicants: Neuropharma, S.A., Instituto Biomar, S.A.
    Inventors: Ana Martinez Gil, Paola Egea, Miguel Medina Padilla, Esther Palomero, Julia Perez Baz, Rosa Fernandez Chimeno, Antonio Medarde Fernandez, Librada Canedo Hernandez, Francisco Romero Millan, Ana Castro Morera, Mercedes Alonso Cascon, Jorge Sanchez Quesada
  • Patent number: 7666885
    Abstract: Compounds of general formula (I): where A, E, G, X, Y and the bond - - - take various meanings are of use in the preparation of a pharmaceutical formulation, for example in the treatment of a disease in which GSK-3 is involved, including Alzheimer's disease or the non-dependent insulin diabetes mellitus, or hyperproliferative disease such as cancer, displasias or metaplasias of tissue, psoriasis, arteriosclerosis or restenosis.
    Type: Grant
    Filed: August 12, 2004
    Date of Patent: February 23, 2010
    Assignees: Consejo Superior de Investigaciones Cientificas, Universidad Autonoma de Madrid (UAM)
    Inventors: Ana Gil Martinez, Ana Castro Morera, Maria Concepcion Martin Perez, Mercedes Alonso Cascon, Isabel Dorronsoro Diaz, Francisco Jose Moreno Munoz, Francisco Wandosell Jurado
  • Publication number: 20100041665
    Abstract: The present invention is related to a family of N-phenyl-prenylamine derivatives of formula (I), and to their use in the treatment of cognitive, neurodegenerative or neuronal diseases or disorders, such as Alzheimer's disease or Parkinson's Disease. The present invention also relates to pharmaceutical compositions comprising the same. Further, the present invention is directed to the use of the compounds in the manufacture of a medicament for the treatment and/or prevention of a cognitive, neurodegenerative or neuronal disease or disorder.
    Type: Application
    Filed: August 1, 2007
    Publication date: February 18, 2010
    Applicant: NOSCIRA, S.A.
    Inventors: Ana Martinez Gil, Ana Castro Morera, Miguel Medina Padilla, Pilar Munoz Ruiz, Javier Lopez Ogalla, Esther Garcia Palomero, Celia De Austria De Luque, Paola Usan Egea, Rita Valenzuela Liminana, Pablo Garcia Fernandez, Elena Delgado Hernandez, Daniel Ignacio Perez Fernandez
  • Publication number: 20090221647
    Abstract: The present invention relates to the use of N-(2-thiazolyl)-amide derivatives of formula (I), for the treatment and/or prophylaxis of a disease in which glycogen synthase kinase 3 (GSK-3) is involved, especially neurodegenerative diseases, such as Alzheimer's disease, or non-insulin dependent diabetes mellitus.
    Type: Application
    Filed: April 27, 2007
    Publication date: September 3, 2009
    Applicant: NOSCIRA, S.A.
    Inventors: Ana Martinez Gil, Ana Castro Morera, Miguel Medina Padilla, Ester Martin Aparicio, Mercedes Alonso Cascon, Ana Fuertes Huerta, Maria Luisa Navarro Rico, Maria Jose Perez Puerto, Maria Del Monte Millan
  • Publication number: 20090192204
    Abstract: The present invention relates to the use of N-(2-thiazolyl)-amide derivatives of formula (I) for the treatment and/or prophylaxis of a disease in which glycogen synthase kinase 3 (GSK-3) is involved, especially neurodegenerative diseases, such as Alzheimer's disease, or non-insulin dependent diabetes mellitus.
    Type: Application
    Filed: April 27, 2007
    Publication date: July 30, 2009
    Applicant: NOSCIRA, S.A.
    Inventors: Ana Martinez Gil, Ana Castro Morera, Miguel Medina Padilla, Ester Martin Aparicio, Mercedes Alonso Cascon, Ana Fuertes Huerta, Maria Luisa Navarro Rico, Maria Jose Perez Puerto, Maria Del Monte Millan
  • Publication number: 20090124686
    Abstract: The invention relates to urea derivatives of formula (I) as inhibitors of glycogen synthase kinase 3?, GSK-3, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use for the treatment and or prophylaxis of a disease in which GSK-3 is involved, such as Alzheimer's disease or non-insulin dependent diabetes mellitus.
    Type: Application
    Filed: July 28, 2006
    Publication date: May 14, 2009
    Applicant: NEUROPHARMA, S.A.
    Inventors: Ana Martinez Gil, Miguel Medina Padilla, Mercedes Alonso Cascon, Ana Fuertes Huerta, Maria Luisa Navarro Rico, Maria Jose Perez Puerto, Ana Castro Morera, Ester Martin Aparicio
  • Publication number: 20090069430
    Abstract: The invention is directed to a compound of formula (I) Having VDCC blocking activity. These compounds are useful for the treatment of a series of human diseases and conditions, especially cognitive or neurodegenerative diseases or conditions.
    Type: Application
    Filed: June 16, 2008
    Publication date: March 12, 2009
    Applicant: NEUROPHARMA, S.A.
    Inventors: Ana MARTINEZ GIL, Ana Castro Morera, Miguel Medina Padilla, Pilar Munoz Ruiz, Laura Rubio Arrieta, Esther Garcia Palomero, Celia De Austria De Luque, Jorge Sanchez-Quesada, Daniel Ignacio Perez Fernandez, Javier Lopez Ogalla, Diana Alonso Gordillo
  • Publication number: 20080275088
    Abstract: The present invention relates to the use of Collismycin and derivatives thereof as inhibitors of oxidative stress in cells and their use for the preparation of medicaments for the treatment and/or prevention of oxidative stress-induced diseases or conditions, especially neurodegenerative diseases, such as Alzheimer's Disease and Parkinson's Disease.
    Type: Application
    Filed: July 28, 2006
    Publication date: November 6, 2008
    Applicants: NEUROPHARMA, S.A., INSTITUTO BIOMAR, S.A.
    Inventors: Ana Martinez Gil, Paola Usan Egea, Miguel Medina Padilla, Esther Garcia Palomero, Julia Perez Baz, Rosa Isabel Fernandez Chimeno, Antonio Medarde Fernandez, Librada Maria Canedo Hernandez, Francisco Romero Millan, Ana Castro Morera, Mercedes Alonso Cascon, Jorge Sanchez Quesada
  • Patent number: 6872737
    Abstract: Compounds of general formula (I): where A, E, G, X, Y and the bond - - - take various meanings are of use in the preparation of a pharmaceutical formulation, for example in the treatment of a disease in which GSK-3 is involved, including Alzheimer's disease or the non-dependent insulin diabetes mellitus, or hyperproliferative disease such as cancer, displasias or metaplasias of tissue, psoriasis, arteriosclerosis or restenosis.
    Type: Grant
    Filed: November 8, 2002
    Date of Patent: March 29, 2005
    Assignee: Consejo Superior de Investigaciones Cientificas
    Inventors: Ana Martinez Gil, Ana Castro Morera, Maria Concepcion Martin Perez, Mercedes Alonso Cascon, Isabel Dorronsoro Diaz, Francisco Jose Moreno Munoz, Francisco Wandosell Jurado
  • Publication number: 20050014803
    Abstract: Compounds of general formula (I): where A, E, G, X, Y and the bond - - - take various meanings are of use in the preparation of a pharmaceutical formulation, for example in the treatment of a disease in which GSK-3 is involved, including Alzheimer's disease or the non-dependent insulin diabetes mellitus, or hyperproliferative disease such as cancer, displasias or metaplasias of tissue, psoriasis, arteriosclerosis or restenosis.
    Type: Application
    Filed: August 12, 2004
    Publication date: January 20, 2005
    Inventors: Ana Martinez, Ana Castro Morera, Maria Martin Perez, Mercedes Cascon, Isabel Diaz, Francisco Moreno Munoz, Francisco Jurado